Intracranial arachnoid cyst: anaesthetic management in pregnancy

2007 ◽  
Vol 16 (3) ◽  
pp. 265-268 ◽  
Author(s):  
M.M. Rupasinghe ◽  
L. McLoughlin ◽  
V. Singaraju
2008 ◽  
Vol 28 (1) ◽  
pp. 48-49
Author(s):  
M.M. Rupasinghe ◽  
L. McLoughlin ◽  
V. Singaraju

1988 ◽  
Vol 8 (3) ◽  
pp. 149
Author(s):  
M. F.M. James ◽  
K. R.L. Huddle ◽  
A. D. Owen ◽  
B. W. Van der Veen

2021 ◽  
pp. 837-898
Author(s):  
James Eldridge ◽  
Nicola Cox ◽  
Alisha Allana ◽  
Heidi Lightfoot

This chapter discusses the anaesthetic management of the pregnant patient, for labour analgesia as well as surgical intervention. It begins with a description of the physiological and pharmacological changes of pregnancy. It describes methods of labour analgesia, including remifentanil, and epidural analgesia and its complications, such as post dural puncture headache (PDPH). It describes anaesthesia for Caesarean section (both regional and general); failed intubation; antacid prophylaxis; postoperative analgesia; retained placenta; in utero fetal death; hypertensive disease of pregnancy (pre-eclampsia, eclampsia and the hypertension, elevated liver enzymes and low platelets (HELLP) syndrome); massive obstetric haemorrhage; placenta praevia and morbidly adherent placenta (placenta accreta, increta and percreta); amniotic fluid embolism (AFE); maternal sepsis, and maternal resuscitation. It discusses comorbidity in pregnancy such as obesity and cardiac disease, and the patient who requires non-obstetric surgery while pregnant. It provides information on safe prescribing in pregnancy and breast-feeding.


2015 ◽  
Vol 06 (04) ◽  
pp. 629-630 ◽  
Author(s):  
V. V. Ramesh Chandra ◽  
B. Chandramowliswara Prasad ◽  
C. Siva Subramanium ◽  
Ravi Kumar

2002 ◽  
Vol 33 (2) ◽  
pp. 19-23
Author(s):  
Motoji MOROZUMI ◽  
Hitoshi MAKINO ◽  
Yumiko UNO ◽  
Tsuyoshi NAKAJIMA ◽  
Kaoru KATO ◽  
...  

Author(s):  
Mirjana Kendrisic ◽  
Borislava Pujic

Advanced maternal age and increasing numbers of women of childbearing age with endocrine and autoimmune disorders have become the challenge for both anaesthetists and obstetricians. Genetic studies have provided new insight into underlying causes of endocrine disorders and prenatal prediction of inheritance. The expression of endocrine disease may influence the interpretation of diagnostic laboratory testing during pregnancy. Better understanding of the pathophysiological mechanisms enables new therapeutic approaches which can compromise pregnancy outcome. Although only a small number of drugs have been shown through clinical studies to be safe for use in pregnancy, intensive therapy for chronic disease is usually needed. Thus, anaesthetic management of women with endocrine disorders in pregnancy has become more complex. The most frequently encountered endocrine disorders during pregnancy include gestational diabetes mellitus and thyroid and adrenal disorders. Gestational diabetes has become increasingly common in pregnant women. Not only does it influence pregnancy outcome, but it also carries a risk for mother and offspring of developing type 2 diabetes later in life. Intensive glucose control may prevent maternal and fetal complications and improve long-term outcome. Pregnancy itself has been found to influence the course of autoimmune diseases, such as rheumatoid arthritis and systemic lupus erythematosus. However, autoimmune diseases may have adverse consequences for maternal, fetal, and neonatal health. There is a relative paucity of literature concerning anaesthetic management of autoimmune diseases. Early recognition and immediate treatment of the common complications have been the key elements to achieving the ultimate goal—good pregnancy outcome.


2014 ◽  
Vol 30 (4) ◽  
pp. e53-e54 ◽  
Author(s):  
Kurt J. Kastenholz ◽  
Lisa J. Rosenthal ◽  
Stephen H. Dinwiddie

Sign in / Sign up

Export Citation Format

Share Document